Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15567770 | 1.00 | GPR6 (0.86) | GPR6CYP2D6 | |
| SCHEMBL17007626 | 1.00 | GPR6 (0.86) | GPR6CYP2D6 | |
| SCHEMBL17007686 | 0.93 | GPR6 (1.00) | GPR6CYP2D6 | |
| SCHEMBL15567884 | 0.93 | GPR6 (1.00) | GPR6CYP2D6 | |
| SCHEMBL17007691 | 0.93 | GPR6 (1.00) | GPR6CYP2D6 | |
| Trifluoroacetic Acid SCHEMBL15566689 | 0.93 | GPR6 (1.00) | GPR6 | |
| Trifluoroacetic Acid SCHEMBL15566691 | 0.93 | GPR6 (1.00) | GPR6 | |
| SCHEMBL17007637 | 0.91 | GPR6 (0.85) | GPR6 | |
| SCHEMBL17007638 | 0.91 | GPR6 (0.85) | GPR6 | |
| SCHEMBL17007674 | 0.91 | GPR6 (0.85) | GPR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10597392-B2 | Tetrahydropyridopyrazines as modulators of GPR6 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-03-24 | — | — | US | claimed |
| US-20190263801-A1 | TETRAHYDROPYRIDOPYRAZINES MODULATORS OF GPR6 | ENVOY THERAPEUTICS, INC. | 2019-08-29 | — | — | US | claimed |
| US-9770452-B2 | Quinoxaline derivatives as GPR6 modulators | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-09-26 | — | — | US | claimed |
| US-20170035775-A1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | ENVOY THERAPEUTICS, INC. | 2017-02-09 | — | — | US | claimed |
| EP-3105230-A1 | PYRIDOPYRAZINES MODULATORS OF GPR6 | Takeda Pharmaceutical Company Limited (JP) | 2016-12-21 | — | — | EP | claimed |
| US-9487526-B2 | Quinoxaline derivatives as GPR6 modulators | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-11-08 | — | — | US | claimed |
| WO-2015123505-A1 | PYRIDOPYRAZINES MODULATORS OF GPR6 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-08-20 | — | — | WO | claimed |
| US-10597392-B2 | Tetrahydropyridopyrazines as modulators of GPR6 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-03-24 | — | — | US | disclosed |
| US-20190263801-A1 | TETRAHYDROPYRIDOPYRAZINES MODULATORS OF GPR6 | ENVOY THERAPEUTICS, INC. | 2019-08-29 | — | — | US | disclosed |
| US-10179783-B2 | Tetrahydropyridopyrazines as modulators of GPR6 | Taketa Pharmaceutical Company Limited (JP) | 2019-01-15 | — | — | US | disclosed |
| US-9770452-B2 | Quinoxaline derivatives as GPR6 modulators | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-09-26 | — | — | US | disclosed |
| US-20170174677-A1 | TETRAHYDROPYRIDOPYRAZINES MODULATORS OF GPR6 | ENVOY THERAPEUTICS, INC. | 2017-06-22 | — | — | US | disclosed |
| US-20170035775-A1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | ENVOY THERAPEUTICS, INC. | 2017-02-09 | — | — | US | disclosed |
| US-9487526-B2 | Quinoxaline derivatives as GPR6 modulators | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-11-08 | — | — | US | disclosed |
| EP-2882722-B1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | TAKEDA PHARMACEUTICAL (JP) | 2016-07-27 | — | — | EP | disclosed |
| US-20150232469-A1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | ENVOY THERAPEUTICS, INC. | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232469-A1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | GPR6, GRM6, GPR65 | GPR6 1/4885CYP2D6 137/4885 |
| US-10597392-B2 | Tetrahydropyridopyrazines as modulators of GPR6 | GPR6, GPR65, GPR52 | GPR6 1/4885CYP2D6 153/4885 |
| US-10179783-B2 | Tetrahydropyridopyrazines as modulators of GPR6 | GPR6, GPR65, GPR52 | GPR6 1/4885CYP2D6 153/4885 |
| US-20190263801-A1 | TETRAHYDROPYRIDOPYRAZINES MODULATORS OF GPR6 | GPR6, GPR52, GPR65 | GPR6 1/4885CYP2D6 161/4885 |
| US-20170035775-A1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | GPR6, GRM6, GPR65 | GPR6 1/4885CYP2D6 137/4885 |
| US-20170174677-A1 | TETRAHYDROPYRIDOPYRAZINES MODULATORS OF GPR6 | GPR6, GPR52, GPR65 | GPR6 1/4885CYP2D6 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.